PsyQ: Journal Club

In this week’s episode of PsyQ, we explore psychiatry’s role in decreasing violence in America. While mental illness is often blamed for violent acts, research shows it accounts for only a small fraction of overall violence. Instead, substance use, social stressors, and access to firearms are far more influential. We discuss how psychiatrists can assess and mitigate risk, the limits of violence prediction, and how tools like red flag laws, crisis intervention teams, and public policy reforms can save lives. The episode highlights practical pearls for clinicians and trainees: focus on modifiable risks, document and act decisively when threats emerge, and embrace psychiatry’s dual role as healer and advocate for safer communities.

In this episode we’ll orient listeners to catatonia’s core features and standard pathways (lorazepam → ECT), then pivot to emerging third-line options when Ativan is ineffective and ECT isn’t feasible. Using a recent systematic review and a bipolar-catatonia case report as anchors, we’ll cover why NMDA antagonism makes mechanistic sense, dosing patterns (most reports used 0.5 mg/kg IV over ~40 min, often as a short series), and what the aggregate signals show: ~80% response and ~44% remission across published cases, with no reported worsening of catatonia or psychosis and only one discontinuation for dissociation. We’ll also highlight real-world scenarios where ketamine helped patients who were medically unfit for ECT (e.g., cardiomyopathy, advanced lung disease) and improved within hours to days—illustrating ketamine’s potential role as a bridge or alternative in treatment-resistant catatonia, especially in mood-disorder presentations.

How should psychiatrists respond when patients use racist language or refuse care based on a clinician’s identity? In this episode, we translate the NEJM five-factor framework into psychiatry’s day-to-day reality—balancing EMTALA obligations and patient autonomy with Title VII protections and clinician well-being—and turn it into practical playbooks for the ED, inpatient units, and clinic. We cover rapid triage in emergencies, capacity and intent assessment (illness-driven vs. bigotry), boundary-setting scripts, when (and when not) to accommodate, safe transfer options, documentation, debriefing, and institution-level policies (codes of conduct, bystander support, reporting pathways). Pearls focus on protecting staff while ensuring care, distinguishing culturally appropriate concordance from prejudice, and leading post-incident team recovery—so trainees can respond clearly, ethically, and confidently.

In this episode, we explore the role of olanzapine/samidorphan (OLZ/SAM) in the treatment of schizophrenia and bipolar I disorder. While olanzapine is one of the most effective second-generation antipsychotics, its use has long been limited by substantial weight gain and metabolic side effects. The addition of samidorphan, an opioid receptor antagonist, represents an innovative approach to mitigate these concerns. We’ll dive into the pathophysiology of schizophrenia and bipolar I disorder, review current treatment strategies, and then unpack the evidence behind OLZ/SAM—including its mechanism of action, clinical trial results, metabolic profile, and potential role in treatment-resistant cases. Along the way, we’ll highlight clinical pearls, prescribing considerations, and real-world implications for psychiatry trainees navigating the complexities of antipsychotic treatment.

Combining aripiprazole and haloperidol presents a clinical and pharmacological puzzle. On one hand, you have haloperidol, a potent D₂ antagonist that fully blocks dopamine; on the other, aripiprazole, a partial agonist with high affinity that displaces the antagonist only to provide a weaker signal. This interplay can be dangerous, potentially triggering a "dopamine supersensitivity psychosis" in a brain already adapted to chronic blockade, leading to a sudden worsening of symptoms. Yet, this same mechanism can be harnessed to treat stubborn side effects like hyperprolactinemia, making it a tempting strategy. In this episode of PsyQ, we dissect the competing pharmacology, review the conflicting case literature—from successful augmentation to severe relapse—and provide evidence-based, practical guidance on how to navigate this combination. Join us for a deep dive into this double-edged sword of psychopharmacology, equipping you with the knowledge to proceed with caution and confidence.

In this episode of PsyQ, we journey from the historical notion of "gut feelings" to the cutting edge of psychiatric research: the microbiota-gut-brain axis. This episode unravels the paradigm shift that recast the gut's microbial inhabitants as a dynamic metabolic organ, actively shaping our mental health. We dissect the core communication network, exploring how neural (vagus nerve), endocrine (HPA stress axis), and immune (cytokine) pathways form a three-way dialogue between our microbes and our mind. Delving into the 'chemical language' of the gut, we discuss how microbial metabolites like short-chain fatty acids and bile acids modulate brain function by influencing key cells like microglia and the integrity of the blood-brain barrier. Finally, we critically examine the clinical implications for disorders like autism and depression, evaluating the current evidence, promises, and pitfalls of therapeutic strategies such as psychobiotics and fecal microbiota transplantation, and look toward the future of this revolutionary field.

References:

Cryan, J. F., & Dinan, T. G. (2012). Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nature Reviews Neuroscience, 13(10), 701–712.

Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y. (2024). Microbiota-gut-brain axis and its therapeutic applications in neurodegenerative diseases. Signal Transduction and Targeted Therapy, 9(1), 37.

Morais, L. H., Schreiber, H. L., & Mazmanian, S. K. (2021). The gut microbiota–brain axis in behaviour and brain disorders. Nature Reviews Microbiology, 19(4), 241–255.

This episode of PsyQ delves into the rare and puzzling condition of non-catatonic mutism in individuals with schizophrenia, a profound silence that is not attributable to the physical inability to speak or the classic signs of catatonia. We explore the case of "Mr. X," a man who was mute for three years, to understand the complexities of diagnosis and the surprising cultural patterns that see this condition reported more frequently in specific regions like the Indian subcontinent. The discussion covers the crucial distinctions from catatonic mutism, potential neurological underpinnings, and the profound psychological impact on patients. Furthermore, we reveal a surprising "game-changer" in treatment, highlighting how ECT, particularly when combined with other medications in a "triple therapy" approach, has shown remarkable success in restoring speech, offering significant hope where conventional treatments have often failed.

The field of psychiatry is at a technological crossroads, with Artificial Intelligence promising to revolutionize care delivery amidst a global mental health crisis. But does this new frontier offer a solution or a source of new, profound harm? This episode of PsyQ: Journal Club takes a critical, evidence-based look at the role of Large Language Models (LLMs) in mental health, moving beyond the hype to provide clinicians with a guide to responsible innovation. We explore a comprehensive framework for safely augmenting clinical practice, examine a case study in using digital phenotyping to forecast mental states in schizophrenia, and confront the chilling evidence of how current "therapy bots" fail in moments of crisis by expressing stigma, colluding with delusions, and dangerously mishandling suicidal ideation. We argue that the future is not the autonomous AI therapist, but a human clinician empowered by validated tools, and we provide a playbook for how psychiatrists can become the essential "ethical guardians" and "digital augurs" in this new era.